Vito Annese

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2434016/publications.pdf

Version: 2024-02-01

178 papers	24,931 citations	17405 63 h-index	7136 153 g-index
185 all docs	185 docs citations	185 times ranked	28215 citing authors

#	Article	IF	Citations
1	Hostâ€“microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature, 2012, 491, 119-124.	13.7	4,038
2	Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nature Genetics, 2010, 42, 1118-1125.	9.4	2,284
3	3rd European Evidence-based Consensus on the Diagnosis and Management of Crohnâ€™s Disease 2016: Part 1: Diagnosis and Medical Management. Journal of Crohn's and Colitis, 2017, 11, 3-25.	0.6	1,547
4	Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nature Genetics, 2011, 43, 246-252.	9.4	1,201
5	ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications. Journal of Crohn's and Colitis, 2019, 13, 144-164K.	0.6	958
6	Pneumatic Dilation versus Laparoscopic Heller's Myotomy for Idiopathic Achalasia. New England Journal of Medicine, 2011, 364, 1807-1816.	13.9	780
7	European evidence based consensus for endoscopy in inflammatory bowel disease. Journal of Crohn's and Colitis, 2013, 7, 982-1018.	0.6	679
8	Inherited determinants of Crohn's disease and ulcerative colitis phenotypes: a genetic association study. Lancet, The, 2016, 387, 156-167.	6.3	607
9	The First European Evidence-based Consensus on Extra-intestinal Manifestations in Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 2016, 10, 239-254.	0.6	577
10	Genome-wide association identifies multiple ulcerative colitis susceptibility loci. Nature Genetics, 2010, 42, 332-337.	9.4	572
11	Common variants at five new loci associated with early-onset inflammatory bowel disease. Nature Genetics, 2009, 41, 1335-1340.	9.4	459
12	Treatment of Relapsing Mild-to-Moderate Ulcerative Colitis With the Probiotic VSL#3 as Adjunctive to a Standard Pharmaceutical Treatment: A Double-Blind, Randomized, Placebo-Controlled Study. American Journal of Gastroenterology, 2010, 105, 2218-2227.	0.2	390
13	Outcomes of Treatment for Achalasia Depend on Manometric Subtype. Gastroenterology, 2013, 144, 718-725.	0.6	387
14	Ulcerative colitisâ€“risk loci on chromosomes 1p36 and 12q15 found by genome-wide association study. Nature Genetics, 2009, 41, 216-220.	9.4	364
15	Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis. Nature Genetics, 2013, 45, 670-675.	9.4	339
16	Long-term Efficacy and Safety of Stem Cell Therapy (Cx601) for Complex Perianal Fistulas in Patients With Crohnâ€™s Disease. Gastroenterology, 2018, 154, 1334-1342.e4.	0.6	331
17	European Evidence-based Consensus: Inflammatory Bowel Disease and Malignancies. Journal of Crohn's and Colitis, 2015, 9, 945-965.	0.6	328
18	Long-term results of the European achalasia trial: a multicentre randomised controlled trial comparing pneumatic dilation versus laparoscopic Heller myotomy. Gut, 2016, 65, 732-739.	6.1	321

#	Article	IF	Citations
19	Advanced Age Is an Independent Risk Factor for Severe Infections and Mortality in Patients Given Antiâ€“Tumor Necrosis Factor Therapy for Inflammatory Bowel Disease. Clinical Gastroenterology and Hepatology, 2011, 9, 30-35.	2.4	316
20	Loci on 20q13 and 21q22 are associated with pediatric-onset inflammatory bowel disease. Nature Genetics, 2008, 40, 1211-1215.	9.4	310
21	Combined Analysis of Genome-wide Association Studies for Crohn Disease and Psoriasis Identifies Seven Shared Susceptibility Loci. American Journal of Human Genetics, 2012, 90, 636-647.	2.6	290
22	ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment. Journal of Crohn's and Colitis, 2022, 16, 2-17.	0.6	288
23	High-density mapping of the MHC identifies a shared role for HLA-DRB1*01:03 in inflammatory bowel diseases and heterozygous advantage in ulcerative colitis. Nature Genetics, 2015, 47, 172-179.	9.4	280
24	ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 2: IBD scores and general principles and technical aspects. Journal of Crohn's and Colitis, 2019, 13, 273-284.	0.6	250
25	Diverse Genome-wide Association Studies Associate the IL12/IL23 Pathway with Crohn Disease. American Journal of Human Genetics, 2009, 84, 399-405.	2.6	246
26	Mapping of multiple susceptibility variants within the MHC region for 7 immune-mediated diseases. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 18680-18685.	3.3	231
27	Meta-analysis of shared genetic architecture across ten pediatric autoimmune diseases. Nature Medicine, 2015, 21, 1018-1027.	15.2	212
28	A Meta-Analysis of Genome-Wide Association Scans Identifies IL18RAP, PTPN2, TAGAP, and PUS10 As Shared Risk Loci for Crohn's Disease and Celiac Disease. PLoS Genetics, 2011, 7, e1001283.	1.5	187
29	Deep Resequencing of GWAS Loci Identifies Rare Variants in CARD9, IL23R and RNF186 That Are Associated with Ulcerative Colitis. PLoS Genetics, 2013, 9, e1003723.	1.5	185
30	Aberrant DNA Methylation in Non-Neoplastic Gastric Mucosa of H. Pylori Infected Patients and Effect of Eradication. American Journal of Gastroenterology, 2007, 102, 1361-1371.	0.2	173
31	HLA-DQA1â€“HLA-DRB1 variants confer susceptibility to pancreatitis induced by thiopurine immunosuppressants. Nature Genetics, 2014, 46, 1131-1134.	9.4	165
32	Comparative genetic analysis of inflammatory bowel disease and type 1 diabetes implicates multiple loci with opposite effects. Human Molecular Genetics, 2010, 19, 2059-2067.	1.4	157
33	Association Between Variants of PRDM1 and NDP52 and Crohn's Disease, Based on Exome Sequencing and Functional Studies. Gastroenterology, 2013, 145, 339-347.	0.6	149
34	Italian consensus conference for colonic diverticulosis and diverticular disease. United European Gastroenterology Journal, 2014, 2, 413-442.	1.6	141
35	Prophylactic administration of somatostatin or gabexate does not prevent pancreatitis after ERCP: an updated meta-analysis. Gastrointestinal Endoscopy, 2007, 65, 624-632.	0.5	130
36	Association of Genetic Variants in NUDT15 With Thiopurine-Induced Myelosuppression in Patients With Inflammatory Bowel Disease. JAMA - Journal of the American Medical Association, 2019, 321, 773.	3.8	129

#	Article	IF	Citations
37	The Italian Society of Gastroenterology (SIGE) and the Italian Group for the study of Inflammatory Bowel Disease (IG-IBD) Clinical Practice Guidelines: The use of tumor necrosis factor-alpha antagonist therapy in Inflammatory Bowel Diseaseâ˜†. Digestive and Liver Disease, 2011, 43, 1-20.	0.4	125
38	The role of glycosylation in IBD. Nature Reviews Gastroenterology and Hepatology, 2014, 11, 588-600.	8.2	123
39	ECCO Guidelines on Therapeutics in Ulcerative Colitis: Surgical Treatment. Journal of Crohn's and Colitis, 2022, 16, 179-189.	0.6	120
40	Variants of CARD15 are Associated with an Aggressive Clinical Course of Crohn's Disease-An IG-IBD Study. American Journal of Gastroenterology, 2005, 100, 84-92.	0.2	116
41	The PROSIT-BIO Cohort. Inflammatory Bowel Diseases, 2017, 23, 233-243.	0.9	116
42	Glycosylation of Immunoglobulin G Associates With Clinical Features of Inflammatory Bowel Diseases. Gastroenterology, 2018, 154, 1320-1333.e10.	0.6	116
43	Maintenance Treatment With Azathioprine in Ulcerative Colitis: Outcome and Predictive Factors After Drug Withdrawal. American Journal of Gastroenterology, 2009, 104, 2760-2767.	0.2	114
44	Common variants in the HLA-DQ region confer susceptibility to idiopathic achalasia. Nature Genetics, 2014, 46, 901-904.	9.4	104
45	DMBT1 Confers Mucosal Protection In Vivo and a Deletion Variant Is Associated With Crohnâ€™s Disease. Gastroenterology, 2007, 133, 1499-1509.	0.6	96
46	Impact of New Treatments on Hospitalisation, Surgery, Infection, and Mortality in IBD: a Focus Paper by the Epidemiology Committee of ECCO. Journal of Crohn's and Colitis, 2016, 10, 216-225.	0.6	96
47	Genetic Variation in Myosin IXB Is Associated With Ulcerative Colitis. Gastroenterology, 2006, 131, 1768-1774.	0.6	95
48	Continuous Infusion Versus Bolus Administration of Steroids in Severe Attacks of Ulcerative Colitis: A Randomized, Double-Blind Trial. American Journal of Gastroenterology, 2007, 102, 601-608.	0.2	95
49	Effect of the BioEnterics intragastric balloon on weight, insulin resistance, and liver steatosis in obese patients. Gastrointestinal Endoscopy, 2010, 71, 927-933.	0.5	93
50	Randomised controlled trial of mesalazine in IBS. Gut, 2016, 65, 82-90.	6.1	91
51	Clinical Features and HLA Association of 5-Aminosalicylate (5-ASA)-induced Nephrotoxicity in Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 2016, 10, 149-158.	0.6	85
52	Plasma N-Glycan Signatures Are Associated With Features ofÂInflammatory Bowel Diseases. Gastroenterology, 2018, 155, 829-843.	0.6	80
53	Polymorphisms of Tumor Necrosis Factor-Î± but Not MDR1 Influence Response to Medical Therapy in Pediatric-Onset Inflammatory Bowel Disease. Journal of Pediatric Gastroenterology and Nutrition, 2007, 44, 171-179.	0.9	76
54	Associations between Genetic Polymorphisms in IL-33, IL1R1 and Risk for Inflammatory Bowel Disease. PLoS ONE, 2013, 8, e62144.	1.1	75

#	Article	IF	Citations
55	Genetics and epigenetics of IBD. Pharmacological Research, 2020, 159, 104892.	3.1	74
56	Adalimumab in active ulcerative colitis: A â€œreal-lifeâ€•observational study. Digestive and Liver Disease, 2013, 45, 738-743.	0.4	72
57	Gastrointestinal motility disorders in inflammatory bowel diseases. World Journal of Gastroenterology, 2014, 20, 37.	1.4	72
58	Erythrocytes-Mediated Delivery of Dexamethasone in Steroid-Dependent IBD Patients-A Pilot Uncontrolled Study. American Journal of Gastroenterology, 2005, 100, 1370-1375.	0.2	71
59	Association of DLG5 R30Q variant with inflammatory bowel disease. European Journal of Human Genetics, 2005, 13, 835-839.	1.4	70
60	Prevalence of celiac disease in inflammatory bowel diseases: An IG-IBD multicentre study. Digestive and Liver Disease, 2010, 42, 175-178.	0.4	70
61	Erythrocyte-Mediated Delivery of Dexamethasone in Patients With Mild-to-Moderate Ulcerative Colitis, Refractory to Mesalamine: A Randomized, Controlled Study. American Journal of Gastroenterology, 2008, 103, 2509-2516.	0.2	66
62	Replication of interleukin 23 receptor and autophagyrelated 16-like 1 association in adult- and pediatric-onset inflammatory bowel disease in Italy. World Journal of Gastroenterology, 2008, 14, 4643.	1.4	66
63	Results of the 4th Scientific Workshop of the ECCO (Group II): Markers of intestinal fibrosis in inflammatory bowel disease. Journal of Crohn's and Colitis, 2014, 8, 1166-1178.	0.6	65
64	The natural history of Crohnâ€™s disease in children: a review of population-based studies. European Journal of Gastroenterology and Hepatology, 2017, 29, 125-134.	0.8	64
65	Evidence of transmission ratio distortion of DLG5 R30Q variant in general and implication of an association with Crohn disease in men. Human Genetics, 2006, 119, 305-311.	1.8	61
66	Topical Treatment of Distal Active Ulcerative Colitis With Beclomethasone Dipropionate or Mesalamine. Journal of Clinical Gastroenterology, 2005, 39, 291-297.	1.1	59
67	Pediatric onset CrohnÊ¼s colitis is characterized by genotype-dependent age-related susceptibility. Inflammatory Bowel Diseases, 2007, 13, 1509-1515.	0.9	58
68	Genetic sharing and heritability of paediatric age of onset autoimmune diseases. Nature Communications, 2015, 6, 8442.	5.8	58
69	The IBD International Genetics Consortium Provides Further Evidence for Linkage to IBD4 and Shows Gene-Environment Interaction. Inflammatory Bowel Diseases, 2005, 11, 1-7.	0.9	57
70	Vitamin D regulates the tight-junction protein expression in active ulcerative colitis. Scandinavian Journal of Gastroenterology, 2016, 51, 1193-1199.	0.6	56
71	PPARÎ³in Inflammatory Bowel Disease. PPAR Research, 2012, 2012, 1-9.	1.1	54
72	Infliximab three-dose induction regimen in severe corticosteroid-refractory ulcerative colitis: Early and late outcome and predictors of colectomy. Journal of Crohn's and Colitis, 2014, 8, 852-858.	0.6	54

#	Article	IF	Citations
73	Systematic review with metaâ€analysis: safety and tolerability of immune checkpoint inhibitors in patients with preâ€existing inflammatory bowel diseases. Alimentary Pharmacology and Therapeutics, 2021, 53, 374-382.	1.9	54
74	An Immunohistochemical Study of the Myenteric Plexus in Idiopathic Achalasia. Journal of Clinical Gastroenterology, 2010, 44, 407-410.	1.1	53
75	Early post-operative endoscopic recurrence in Crohn's disease patients: Data from an Italian Group for the study of inflammatory bowel disease (IG-IBD) study on a large prospective multicenter cohort. Journal of Crohn's and Colitis, 2014, 8, 1217-1221.	0.6	53
76	Investigation of Multiple Susceptibility Loci for Inflammatory Bowel Disease in an Italian Cohort of Patients. PLoS ONE, 2011, 6, e22688.	1.1	53
77	The PROSIT Cohort of Infliximab Biosimilar in IBD: A Prolonged Follow-up on the Effectiveness and Safety Across Italy. Inflammatory Bowel Diseases, 2019, 25, 568-579.	0.9	51
78	Mucosal healing in inflammatory bowel disease: Treatment efficacy and predictive factors. Digestive and Liver Disease, 2013, 45, 978-985.	0.4	50
79	Systematic analysis of circadian genes using genome-wide cDNA microarrays in the inflammatory bowel disease transcriptome. Chronobiology International, 2015, 32, 903-916.	0.9	50
80	A protein-truncating R179X variant in RNF186 confers protection against ulcerative colitis. Nature Communications, 2016, 7, 12342.	5.8	50
81	Oral Prolonged Release Beclomethasone Dipropionate and Prednisone in the Treatment of Active Ulcerative Colitis: Results From a Double-Blind, Randomized, Parallel Group Study. American Journal of Gastroenterology, 2015, 110, 708-715.	0.2	48
82	Direct or indirect association in a complex disease: the role ofSLC22A4 andSLC22A5 functional variants in Crohn disease. Human Mutation, 2006, 27, 778-785.	1.1	47
83	Use of corticosteroids and immunosuppressive drugs in inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease. Digestive and Liver Disease, 2017, 49, 604-617.	0.4	47
84	Gastric Emptying of Solids in Patients with Nonobstructive CrohnÊ¼s Disease Is Sometimes Delayed. Journal of Clinical Gastroenterology, 1995, 21, 279-282.	1.1	42
85	Safety of treatments for inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). Digestive and Liver Disease, 2017, 49, 338-358.	0.4	42
86	Non-surgical treatment of esophageal achalasia. World Journal of Gastroenterology, 2006, 12, 5763.	1.4	42
87	Gallbladder function and gastric liquid emptying in achalasia. Digestive Diseases and Sciences, 1991, 36, 1116-1120.	1.1	39
88	Use of biosimilars in inflammatory bowel disease: Statements of the Italian Group for Inflammatory Bowel Disease. Digestive and Liver Disease, 2014, 46, 963-968.	0.4	39
89	Association Study of a Polymorphism in Clock GenePERIOD3and Risk of Inflammatory Bowel Disease. Chronobiology International, 2012, 29, 994-1003.	0.9	38
90	A review of extraintestinal manifestations and complications of inflammatory bowel disease. Saudi Journal of Medicine and Medical Sciences, 2019, 7, 66.	0.3	38

#	Article	IF	Citations
91	CARD15 Gene Variants and Risk of Reoperation in Crohn's Disease Patients. American Journal of Gastroenterology, 2009, 104, 2483-2491.	0.2	37
92	Global variability of the human IgG glycome. Aging, 2020, 12, 15222-15259.	1.4	37
93	Use of biosimilars in inflammatory bowel disease: a position update of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). Digestive and Liver Disease, 2019, 51, 632-639.	0.4	36
94	Evaluating the role of the genetic variations of PTPN22, NFKB1, and FcGRIIIA genes in inflammatory bowel disease: A meta-analysis. Inflammatory Bowel Diseases, 2007, 13, 1212-1219.	0.9	35
95	Novel NOD2 haplotype strengthens the association between TLR4 Asp299gly and CrohnÊ¼s disease in an Australian population. Inflammatory Bowel Diseases, 2008, 14, 585-590.	0.9	35
96	Disease patterns in late-onset ulcerative colitis: Results from the IG-IBD â€œAGED studyâ€• Digestive and Liver Disease, 2017, 49, 17-23.	0.4	35
97	Mucosal NOD2 expression and NF-ÎºB activation in pediatric CrohnÊ¼s disease. Inflammatory Bowel Diseases, 2008, 14, 295-302.	0.9	32
98	Promoter methylation of the MGAT3 and BACH2 genes correlates with the composition of the immunoglobulin G glycome in inflammatory bowel disease. Clinical Epigenetics, 2018, 10, 75.	1.8	32
99	CARD15 Genotyping in Inflammatory Bowel Disease Patients by Multiplex Pyrosequencing. Clinical Chemistry, 2003, 49, 1675-1679.	1.5	30
100	Prospective Evaluation of Liver Stiffness Using Transient Elastography in Alcoholic Patients Following Abstinence. Alcohol and Alcoholism, 2017, 52, 42-47.	0.9	29
101	Contribution of IBD5 Locus to Clinical Features of IBD Patients. American Journal of Gastroenterology, 2006, 101, 318-325.	0.2	27
102	European Crohn's and Colitis Organisation Topical Review on environmental factors in IBD. Journal of Crohn's and Colitis, 2017, 11, jjw223.	0.6	27
103	Genome-Wide Expression Profiling Identifies an Impairment of Negative Feedback Signals in the Crohnâ€™s Disease-Associated NOD2 Variant L1007fsinsC. Journal of Immunology, 2011, 186, 4027-4038.	0.4	25
104	CT-P13: design, development, and place in therapy. Drug Design, Development and Therapy, 2017, Volume 11, 1653-1661.	2.0	25
105	Haplotype-based association analysis of 56 functional candidate genes in the IBD6 locus on chromosome 19. European Journal of Human Genetics, 2006, 14, 780-790.	1.4	24
106	High resolution melting (HRM) analysis for the detection of ER22/23EK, BclI, and N363S polymorphisms of the glucocorticoid receptor gene. Journal of Steroid Biochemistry and Molecular Biology, 2009, 113, 269-274.	1.2	23
107	Neuroimmune interactions in patients with inflammatory bowel diseases: Disease activity and clinical behavior based on Substance P serum levels. Journal of Crohn's and Colitis, 2012, 6, 563-570.	0.6	23
108	Variants at the 3p21 locus influence susceptibility and phenotype both in adults and early-onset patients with inflammatory bowel disease. Inflammatory Bowel Diseases, 2010, 16, 1108-1117.	0.9	22

#	Article	IF	Citations
109	Erythrocytes-mediated Delivery of Dexamethasone 21-phosphate in Steroid-dependent Ulcerative Colitis. Inflammatory Bowel Diseases, 2013, 19, 1.	0.9	22
110	Genome-wide Pathway Analysis Using Gene Expression Data of Colonic Mucosa in Patients with Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2015, 21, 1.	0.9	22
111	Successful induction of clinical response and remission with certolizumab pegol in CrohnÊ¼s disease patients refractory or intolerant to infliximab: A real-life multicenter experience of compassionate use. Inflammatory Bowel Diseases, 2008, 14, 1168-1170.	0.9	21
112	Genetic variation in thelymphotoxin-Î±(LTA)/tumour necrosis factor-Î±(TNFÎ±) locus as a risk factor for idiopathic achalasia. Gut, 2014, 63, 1401-1409.	6.1	21
113	Safety profile of methotrexate in inflammatory bowel disease. Expert Opinion on Drug Safety, 2016, 15, 1427-1437.	1.0	21
114	The HLA-DQÎ²1 insertion is a strong achalasia risk factor and displays a geospatial northâ€“south gradient among Europeans. European Journal of Human Genetics, 2016, 24, 1228-1231.	1.4	21
115	Enteropathic spondyloarthropathy: A common genetic background with inflammatory bowel disease?. World Journal of Gastroenterology, 2009, 15, 2456.	1.4	21
116	Comparative efficacy of first-line therapeutic interventions for achalasia: a systematic review and network meta-analysis. Surgical Endoscopy and Other Interventional Techniques, 2021, 35, 4305-4314.	1.3	20
117	Comparison of four proton pump inhibitors for the short-term treatment of esophagitis in elderly patients. World Journal of Gastroenterology, 2007, 13, 4467.	1.4	19
118	Analysis of Candidate Genes on Chromosomes 5q and 19p in Celiac Disease. Journal of Pediatric Gastroenterology and Nutrition, 2007, 45, 180-186.	0.9	18
119	Is green tea a potential trigger for autoimmune hepatitis?. Phytomedicine, 2013, 20, 1186-1189.	2.3	18
120	Alleleâ€specific transcriptional activity of the variable number of tandem repeats of the inducible nitric oxide synthase gene is associated with idiopathic achalasia. United European Gastroenterology Journal, 2017, 5, 200-207.	1.6	17
121	Association between Polymorphisms in Antioxidant Genes and Inflammatory Bowel Disease. PLoS ONE, 2017, 12, e0169102.	1.1	17
122	Chronic inflammatory diseases: Do immunological patterns drive the choice of biotechnology drugs? A critical review. Autoimmunity, 2014, 47, 287-306.	1.2	16
123	Disease Course and Colectomy Rate of Ulcerative Colitis. Inflammatory Bowel Diseases, 2016, 22, 1945-1953.	0.9	16
124	IL-1Î²-511 and IL-1RN*2 polymorphisms in inflammatory bowel disease: An Italian population study and meta-analysis of European studies. Digestive and Liver Disease, 2010, 42, 179-184.	0.4	15
125	Late-onset Crohnâ€™s disease: a comparison of disease behaviour and therapy with younger adult patients: the Italian Group for the Study of Inflammatory Bowel Disease â€˜AGEDâ€™ study. European Journal of Gastroenterology and Hepatology, 2019, 31, 1361-1369.	0.8	14
126	Therapeutic landscape for ulcerative colitis: where is the Adacolumn® system and where should it be?. Clinical and Experimental Gastroenterology, 2013, 6, 1.	1.0	13

#	Article	IF	Citations
127	New endoscopic imaging techniques in surveillance of inflammatory bowel disease. World Journal of Gastrointestinal Endoscopy, 2015, 7, 230.	0.4	13
128	Peroral Endoscopic Myotomy for the Treatment of Esophageal Diverticula. Journal of Clinical Gastroenterology, 2022, 56, 853-862.	1.1	13
129	First United Arab Emirates consensus on diagnosis and management of inflammatory bowel diseases: A 2020 Delphi consensus. World Journal of Gastroenterology, 2020, 26, 6710-6769.	1.4	12
130	Biosimilars in inflammatory bowel disease: A review of post-marketing experience. World Journal of Gastroenterology, 2017, 23, 197.	1.4	11
131	Beclomethasone dipropionate in Crohn's ileitis: A randomised, double-blind trial. Digestive and Liver Disease, 2011, 43, 459-464.	0.4	10
132	Pre- and post-procedural quality indicators for colonoscopy: A nationwide survey. Digestive and Liver Disease, 2016, 48, 759-764.	0.4	10
133	Addition of Granulocyte/Monocyte Apheresis to Oral Prednisone for Steroid-dependent Ulcerative Colitis: A Randomized Multicentre Clinical Trial. Journal of Crohn's and Colitis, 2018, 12, 687-694.	0.6	10
134	Linear IgA bullous dermatosis andÂulcerative colitis treated byÂproctocolectomy. European Journal of Dermatology, 2009, 19, 651-651.	0.3	10
135	Roundtable on biosimilars with European regulators and medical societies, Brussels, Belgium, 12 January 2016. GaBI Journal, 2016, 5, 74-83.	0.4	9
136	Optimizing biologic therapy in inflammatory bowel disease: a Delphi consensus in the United Arab Emirates. Therapeutic Advances in Gastroenterology, 2021, 14, 175628482110653.	1.4	9
137	History of cancer in first degree relatives of Barrett's esophagus patients: A case-control study. Clinics and Research in Hepatology and Gastroenterology, 2011, 35, 831-838.	0.7	8
138	Impact of genetic polymorphisms on the pathogenesis of idiopathic achalasia: Association with IL33 gene variant. Human Immunology, 2014, 75, 364-369.	1.2	8
139	Outcome of acute severe ulcerative colitis in patients previously exposed to immunosuppressive therapy. Digestive and Liver Disease, 2016, 48, 1432-1437.	0.4	8
140	Dissecting genetic predisposition to inflammatory bowel disease: current progress and prospective application. Expert Review of Clinical Immunology, 2007, 3, 287-298.	1.3	7
141	Treatment of steroid-naive ulcerative colitis. Expert Opinion on Pharmacotherapy, 2009, 10, 1449-1460.	0.9	7
142	IL23R, ATG16L1, IRGM, OCTN1, and OCTN2 mRNA expression in inflamed and noninflamed mucosa of IBD patients. Inflammatory Bowel Diseases, 2011, 17, 1832-1833.	0.9	7
143	Ustekinumab: moving the target from psoriasis to Crohn's disease. Expert Review of Gastroenterology and Hepatology, 2014, 8, 5-13.	1.4	7
144	Smoking as an independent determinant of Barrettâ€™s esophagus and, to a lesser degree, of reflux esophagitis. Cancer Causes and Control, 2015, 26, 419-429.	0.8	7

#	Article	IF	Citations
145	Metabolomic analysis with 1 H-NMR for non-invasive diagnosis of hepatic fibrosis degree in patients with chronic hepatitis C. Digestive and Liver Disease, 2017, 49, 1338-1344.	0.4	7
146	Su1762 Clinical and Molecular Characterization of Medically Refractory Acute, Severe Colitis: Preliminary Results From the International Inflammatory Bowel Disease Genetics Consortium (IIBDGC) Immunochip Study. Gastroenterology, 2013, 144, S-470.	0.6	6
147	Risk of Postâ€“Endoscopic Retrograde Cholangiopancreatography Pancreatitis and Ways to Prevent It: Old Myths, a Current Need? The Case of Allopurinol. Clinical Gastroenterology and Hepatology, 2008, 6, 374-376.	2.4	5
148	Discovering genetic variants in Crohn's disease by exploring genomic regions enriched of weak association signals. Digestive and Liver Disease, 2011, 43, 623-631.	0.4	5
149	Emerging drug for diarrhea predominant irritable bowel syndrome. Expert Opinion on Emerging Drugs, 2015, 20, 247-261.	1.0	5
150	Percutaneous ultrasound-guided fiducial marker placement for liver cancer robotic stereotactic radio-surgery treatment: A comparative analysis of three types of markers and needles. Arab Journal of Gastroenterology, 2017, 18, 83-86.	0.4	5
151	Genetics and Ulcerative Colitis: What are the Clinical Implications?. Current Drug Targets, 2011, 12, 1383-1389.	1.0	4
152	Genetic variants of membrane metallopeptidase genes in inflammatory bowel diseases. Digestive and Liver Disease, 2013, 45, 1003-1010.	0.4	4
153	Capsule endoscopy in Crohn's disease: Is there enough light in the tunnel?. Journal of Crohn's and Colitis, 2014, 8, 1598-1600.	0.6	4
154	Small Bowel Adenocarcinoma in Crohnâ€™s Disease: An Underestimated Risk?. Journal of Crohn's and Colitis, 2020, 14, 285-286.	0.6	4
155	Association of genetic profiles to Crohnâ€™s disease by linear combinations of single nucleotide polymorphisms. Artificial Intelligence in Medicine, 2009, 46, 131-138.	3.8	3
156	The genetic burden of inflammatory bowel diseases: implications for the clinic?. Expert Review of Gastroenterology and Hepatology, 2016, 10, 1109-1117.	1.4	3
157	New biologics in the management of Crohn's disease: focus on certolizumab pegol. Clinical and Experimental Gastroenterology, 2009, 2, 61-8.	1.0	3
158	Beclomethasone dipropionate for the treatment of ulcerative colitis. Expert Opinion on Orphan Drugs, 2015, 3, 87-96.	0.5	2
159	Genetic risk variants as therapeutic targets for Crohnâ€™s disease. Expert Opinion on Therapeutic Targets, 2017, 21, 381-390.	1.5	2
160	Crohn's Colitis: Development of a multiplex gene expression assay comparing mRNA levels of susceptibility genes. Clinics and Research in Hepatology and Gastroenterology, 2017, 41, 435-444.	0.7	2
161	Computed tomography or contrastâ€enhanced ultrasonography for followâ€up of liver metastases after Cyberknife therapy?: A prospective pilot study. Journal of Ultrasound in Medicine, 2019, 38, 649-655.	0.8	2
162	Prevalence and Predictors of Reduced Bone Density in Child and Adolescent Patients With Crohn's Disease. Journal of Clinical Densitometry, 2021, 24, 252-258.	0.5	2

#	Article	IF	Citations
163	Giant esophageal lipoma. Updates in Surgery, 2011, 63, 125-127.	0.9	1
164	RS-SNP: a random-set method for genome-wide association studies. BMC Genomics, 2011, 12, 166.	1.2	1
165	Dissecting the mucosal expression of human leucine-rich repeat family genes in inflammatory bowel disease patients. Inflammatory Bowel Diseases, 2011, 17, 1834-1835.	0.9	1
166	An update on treatment of ulcerative colitis. Expert Opinion on Orphan Drugs, 2019, 7, 295-304.	0.5	1
167	IBD and malignancies: The gender matters. Digestive and Liver Disease, 2020, 52, 156-157.	0.4	1
168	Infliximab is more effective than cyclosporine as a rescue therapy for acute severe ulcerative colitis: a retrospective single-center study. Annals of Gastroenterology, 2021, 34, 370-377.	0.4	1
169	Percutaneous ultrasound-guided bowel biopsy of a pseudokidney mass. Turkish Journal of Gastroenterology, 2017, 28, 60-62.	0.4	1
170	Digging out CrohnÊ¼s disease genes. Inflammatory Bowel Diseases, 2009, 15, 1436-1437.	0.9	0
171	Botulinum neurotoxin in the gastrointestinal tract. , 0, , 278-287.		0
172	Authorsâ€™ answers on comment of Abellona et al. on Metabolomic analysis for noninvasive diagnosis of hepatic fibrosis degree in patients with chronic hepatitis C. Digestive and Liver Disease, 2018, 50, 210-211.	0.4	0
173	Biosimilars in IBD: Similarity Breeds Contented Patients. Digestive Diseases and Sciences, 2019, 64, 1399-1400.	1.1	0
174	TDM of Anti-TNF Agents: The Importance of Being Active!. Inflammatory Bowel Diseases, 2020, 26, 271-272.	0.9	0
175	A further â€œstri(v)deâ€•in IBD management. Digestive and Liver Disease, 2020, 52, 721-722.	0.4	0
176	Biosimilars in Inflammatory Bowel Disease: Angels or Demons?. Gastroenterology & Hepatology (Bartlesville, Okla), 2016, 5, .	0.0	0
177	Biosimilars in Italy: a gastroenterologistâ€™s view. GaBI Journal, 2016, 5, 131-133.	0.4	0
178	Prediction of Crohnâ€™s Disease by Profiles of Single Nucleotide Polymorphisms. Lecture Notes in Computer Science, 2008, , 564-571.	1.0	0